レメディ・アンド・カンパニー株式会社 provides a platform for drug development, with expertise in global development, oncology, regenerative medicine, and digital innovation. Self-described as supporting advanced drug development and addressing challenges in health sciences.

レメディ・アンド・カンパニー株式会社

Remedy &amp; Company Corporation | 793 followers on LinkedIn. Remedy &amp; Company Corporation (formerly known as intellim Holdings Corporation) was established in 2018.
Its predecessor, intellim Corporation, which was founded in 2005 with main aim of developing CRO business.
Subsequently, intellim Holdings Corporation (now known as Remedy &amp; Company Corporation) was established in 2018 as the core driving intellim Corporation and other group companies in Japan and abroad to create innovative solutions in drug development within Japan and abroad.

Dedicated to develop global projects - Consultant & Project manager for VR application - Business Consultant APAC, Africa, MENA and Japan - Business…

Peggy Heure

Global Collaboration Department at intellim Holdings Corporation

Henggar Pramudityo

Remedy & Company, Executive Managing Director of Global business division

Tomoko Eguchi

Program Consultant, Vennue Foundation. Business Development, Remedy and Company, Bangladesh

Tajnin Ahmed

Remedy & Company Corporation

＼ 開催まであと9日！ ／ 📢オンコロジーセミナー開催情報📢 ※弊社グループ会社（株式会社インテリム）が主催するセミナー情報です。 株式会社インテリムは、 2024年11月15日に「がんゲノムについての最新知見 保険診療で行われる遺伝子パネル検査を基盤としたがんゲノム医療とデータ利活用」と題したオンコロジーセミナーを開催します。 講師には、国立がん研究センター がんゲノム情報管理センター(C-CAT) センター長の河野隆志先生をお招きし、インテリムの特別顧問である西條長宏先生（東京医科大学客員教授）が司会を務められます。 🔵 セミナー詳細 【日時】2024年11月15日（金） 18:30~19:30 （開場 18:00） ※講演会終了後、情報交換会を予定（20:30終了予定） 【会場】ＴＫＰガーデンシティPREMIUM東京駅丸の内中央 ホール12-I 東京都千代田区丸の内1-9-1 丸の内中央ビル 12階 【参加費】 ￥4,000（税込） 【定員】60名（満席になり次第受付終了） 【参加申込み】以下よりお申込みください。 https://lnkd.in/gSXaQDZH ... 🔵 こんな方におすすめです ・製薬企業にてオンコロジー領域を担当されている方 ・製薬企業にて分子標的治療薬の開発を担当されている方 ・ゲノム医療に興味をお持ちの方 ※ご参加は、製薬企業勤務の方に限らせていただきます（メディアを除く） 詳細はインテリムのHPでご確認ください https://lnkd.in/gCm2PmjD

💥 MUGEN: Evolving with New eConsent, ePRO, and eTMF Capabilities. At Remedy & Company, we’re proud to highlight MUGEN, our innovative Clinical Data Management Platform accelerating drug approval processes since its inception. Developed entirely in-house in Japan, MUGEN CDMS platform now is added with ePro, eConsent, and eTMF functionalities to streamline clinical trials globally. With MUGEN, we centralise data collection from research facilities, medical institutions, and patients, ensuring efficient storage and analysis of large data volumes. By leveraging our collaboration with our CRO business, we provide a comprehensive one-stop solution that seamlessly manages everything from clinical trial planning to system construction, data analysis, and drug approval applications. Here’s to continuing our journey in transforming drug development! 💊✨ Connect with us now to learn more about our EDC platform our EDC platform and the exclusive offers: https://lnkd.in/gDwjbNJv #ClinicalTrials #DataManagement #DrugApproval #Innovation #Healthcare #MUGEN

At Remedy & Company, as a leading Japanese HealthTech Platform, backed by an expert's global team from diverse backgrounds; not only excel in technical requirements but also possess a nuanced understanding of the cultural dynamics across Asia. This dual expertise enables us to provide solutions to meet the unique client's needs of each market. We remain committed to fostering strong partnerships and driving innovative research initiatives. Together, we are looking for transforming the clinical research landscape and delivering impactful results for our clients. Ready to collaborate? Talk to our team: https://lnkd.in/gDwjbNJv #CRO #ClinicalTrials #Japan #Pharmaceuticals #Biotech #Healthcare #Innovation #ClinicalResearch #Remedy

Expand your Clinical Development to Japan!!. Remedy & Company Corporation as a Global Health Tech Platform offers a full scope of CRO services in Japan, with more than 20 years of experience supporting pharmaceutical and biotech companies in achieving success in their clinical trials. With a dedicated team of local experts, we ensure seamless project execution while navigating Japan's regulatory landscape. Let us be your trusted partner in advancing healthcare innovation! Let's connect! https://lnkd.in/gDwjbNJv #CRO #ClinicalTrials #Japan #Pharmaceuticals #Biotech #Healthcare #Innovation #ClinicalResearch #Remedy

Unlock the potential of your pharmaceutical development with our expansive global reach. At Remedy & Company Corporation, we offer comprehensive support across in Asia, Africa, and LATAM, ensuring that your clinical trials are conducted efficiently, ethically, and with full regulatory compliance. Partner with us to navigate the complexities of global trials and bring your innovations to market faster and with confidence. Learn more about our global scope here: https://lnkd.in/gQp93acf

Remedy & Company Co., Ltd. is thrilled to announce a strategic partnership with Oxford LATAM Research Group to enhance clinical trials and network development across South America. This collaboration with a leading entity in infectious disease research will allow us to conduct trials for Japanese-origin treatments, vaccines, and diagnostics, especially for challenging infectious diseases such as NTDs, tuberculosis, and malaria. Furthermore, our agreements with Oxford LATAM and Universidad Peruana Cayetano Heredia in Peru expand our "Global Infectious Disease Development Platform," reaching over 500,000 potential trial participants. As a leader in Asia's infectious disease field, Remedy & Company is dedicated to delivering greater value and choice to our clients by fostering networks in regions where trials are essential. Let's work together to tackle global health challenges and pioneer innovative solutions! #GlobalHealth #ClinicalTrials #InfectiousDiseases #Innovation #Healthcare #Remedy https://lnkd.in/g5Vv9Gkh

We are pleased to announce that Remedy & Company has entered a strategic partnership with Universidad Peruana Cayetano Heredia, a prestigious institution in South America (Peru) known for its advanced research in infectious diseases. This collaboration aims to conduct clinical trials in South America using Japanese pharmaceutical innovations, focusing on challenging diseases such as dengue fever, malaria, tuberculosis, and neglected tropical diseases (NTDs). By expanding our network and expertise in the region, we are committed to enhancing global health and preparing for future pandemics. #GlobalHealth #InfectiousDiseases #ClinicalTrials #Pharmaceuticals #Remedy #Peru https://lnkd.in/gqitUqdG

We are thrilled to announce that Remedy & Company has officially launched a groundbreaking Virtual Entertainment Division! This new venture aims to harness the soothing and heartwarming power of VTubers to bring innovative solutions worldwide. By leveraging our expertise in digital content development, we aspire to transcend boundaries and deliver unprecedented forms of comfort globally. Join us on this exciting journey as we continue to innovate and expand our horizons. Discover more about this venture and our collaboration with VTuber Hiyo Amai here. https://lnkd.in/gMbR3v4A #HealthcareInnovation #VirtualEntertainment #VTuber #DigitalTransformation #Remedy #GlobalHealth

Remedy & Company Corporation is proud to announce our recent Memorandum of Understanding (MOU) with Airlangga University Hospital in Indonesia. This collaboration aims to advance clinical trials for infectious diseases and introduce the Controlled Human Infection Model (CHIM) studies to the region. Leveraging Airlangga's expertise in Neglected Tropical Diseases (NTDs) and our extensive experience across South Global countries, we’re set to enhance clinical trial capabilities and accelerate the development of safe, effective vaccines and treatments. Together, we’re committed to pioneering innovative and ethical approaches to tackling some of the world's most pressing health challenges. Stay tuned as we work towards our mission of transformative global health solutions! #ClinicalTrials #InfectiousDiseases #Remedy #Innovation #CHIMStudies https://lnkd.in/g5EbmNgV

Remedy & Company has signed an MOU with Indonesia's Clinical Research Coordinator (INA CRC) to boost pharmaceutical development and introduce Japan-stemmed clinical trials in Indonesia. This collaboration leverages our extensive experience in Asia to enhance Indonesia’s clinical trial capabilities and accelerate the development of vaccines and treatments for infectious diseases. We are committed to advancing global health and preparing for future pandemics. Contact with us on this journey to innovate and strengthen healthcare worldwide! #ClinicalTrials #GlobalHealth #Pharmaceuticals #Innovation #Indonesia Link of the news： https://lnkd.in/gefPjwTx

news impact assignment basic	general
public peers	general	Nov 7, 2024 8:38 PM	e8b4b97b
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 7, 2024 8:38 PM	b179e7c8
crunchbase trigger	general	Nov 7, 2024 8:38 PM	9bc0e77a
crunchbase profile	general
li profile	general	Nov 7, 2024 8:38 PM	245c94c3
translate crunchbase fundingrounds	general
peers	general	Nov 7, 2024 8:38 PM	e7e808d0
news basic	general	Nov 7, 2024 8:38 PM	8386bbcf
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

REME

COM:REMEDY-COMPANY

レメディ・アンド・カンパニー株式会社